Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia.
作者信息
Akbarzadeh Mohammad Amin, Vaez-Gharamaleki Yosra, Hosseini Mohammad-Salar
机构信息
Research Center for Evidence-Based Medicine, Iranian EBM Center: A JBI Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
出版信息
Ther Adv Hematol. 2024 Dec 11;15:20406207241306553. doi: 10.1177/20406207241306553. eCollection 2024.
Abstract
摘要
相似文献
1
Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia.急性白血病中对组蛋白脱乙酰酶抑制剂耐药的机制。
Ther Adv Hematol. 2024 Dec 11;15:20406207241306553. doi: 10.1177/20406207241306553. eCollection 2024.
2
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?组蛋白去乙酰化酶 8（HDAC8）抑制剂在血液系统恶性肿瘤，特别是急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）中是否有效？
Eur J Med Chem. 2023 Oct 5;258:115594. doi: 10.1016/j.ejmech.2023.115594. Epub 2023 Jun 25.
3
Histone deacetylase inhibitors for leukemia treatment: current status and future directions.组蛋白去乙酰化酶抑制剂治疗白血病：现状与未来方向。
Eur J Med Res. 2024 Oct 26;29(1):514. doi: 10.1186/s40001-024-02108-8.
4
Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review.急性淋巴细胞白血病中针对组蛋白去乙酰化酶抑制剂的当前治疗策略：一项系统综述
Front Oncol. 2024 Feb 21;14:1324859. doi: 10.3389/fonc.2024.1324859. eCollection 2024.
5
Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia.组蛋白去乙酰化酶抑制剂：靶向表观遗传调控治疗急性白血病
Ther Adv Hematol. 2024 Oct 16;15:20406207241283277. doi: 10.1177/20406207241283277. eCollection 2024.
6
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.组蛋白去乙酰化酶抑制剂在血液系统恶性肿瘤治疗中的作用机制。
Cancer Sci. 2016 Nov;107(11):1543-1549. doi: 10.1111/cas.13062. Epub 2016 Nov 4.
7
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.组蛋白去乙酰化酶6作为B细胞相关血液系统恶性肿瘤的治疗靶点
Front Pharmacol. 2020 Jun 26;11:971. doi: 10.3389/fphar.2020.00971. eCollection 2020.
8
Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?白细胞介素-15 是否能增强血液恶性肿瘤中组蛋白去乙酰化酶抑制剂的作用？
Med Hypotheses. 2013 Aug;81(2):311-5. doi: 10.1016/j.mehy.2013.04.021. Epub 2013 May 10.
9
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.急性髓系白血病的表观遗传学治疗：低甲基化剂、组蛋白去乙酰化酶抑制剂的作用以及低甲基化剂与组蛋白去乙酰化酶抑制剂联合应用。
Chin Med J (Engl). 2020 Mar 20;133(6):699-715. doi: 10.1097/CM9.0000000000000685.
10
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.组蛋白去乙酰化酶抑制剂可使人类急性白血病细胞中的zeste 2增强子及相关的多梳抑制复合物2蛋白减少。
Mol Cancer Ther. 2006 Dec;5(12):3096-104. doi: 10.1158/1535-7163.MCT-06-0418.
本文引用的文献
1
Histone deacetylase inhibitors for leukemia treatment: current status and future directions.组蛋白去乙酰化酶抑制剂治疗白血病：现状与未来方向。
Eur J Med Res. 2024 Oct 26;29(1):514. doi: 10.1186/s40001-024-02108-8.
2
Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia.组蛋白去乙酰化酶抑制剂：靶向表观遗传调控治疗急性白血病
Ther Adv Hematol. 2024 Oct 16;15:20406207241283277. doi: 10.1177/20406207241283277. eCollection 2024.
3
Cancer stem cells: advances in knowledge and implications for cancer therapy.癌症干细胞：知识进展及其对癌症治疗的影响。
Signal Transduct Target Ther. 2024 Jul 5;9(1):170. doi: 10.1038/s41392-024-01851-y.
4
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.普拉西诺司他联合阿扎胞苷治疗不适合标准诱导化疗的新诊断成人急性髓系白血病（AML）患者：PRIMULA 期 3 研究。
Leuk Res. 2024 May;140:107480. doi: 10.1016/j.leukres.2024.107480. Epub 2024 Mar 12.
5
Dysregulation of different modes of programmed cell death by epigenetic modifications and their role in cancer.表观遗传修饰对不同类型细胞程序性死亡的调控及其在癌症中的作用。
Cancer Lett. 2024 Mar 1;584:216623. doi: 10.1016/j.canlet.2024.216623. Epub 2024 Jan 20.
6
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?组蛋白去乙酰化酶 8（HDAC8）抑制剂在血液系统恶性肿瘤，特别是急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）中是否有效？
Eur J Med Chem. 2023 Oct 5;258:115594. doi: 10.1016/j.ejmech.2023.115594. Epub 2023 Jun 25.
7
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.贝林司他和阿伐司特布治疗复发/难治性髓系恶性肿瘤患者的 1 期研究。
Cancer Chemother Pharmacol. 2023 Mar;91(3):281-290. doi: 10.1007/s00280-023-04511-0. Epub 2023 Mar 2.
8
Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells.ABCB1的过表达与癌细胞对KRAS-G12C特异性抑制剂ARS-1620的耐药性相关。
Front Pharmacol. 2022 Feb 23;13:843829. doi: 10.3389/fphar.2022.843829. eCollection 2022.
9
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.依替诺司他联合克拉屈滨治疗低危费城染色体阴性（新诊断老年患者或复发难治患者）急性淋巴细胞白血病或双表型白血病的 1 期临床研究。
Leuk Res. 2021 Nov;110:106707. doi: 10.1016/j.leukres.2021.106707. Epub 2021 Sep 10.
10
Targeting epigenetic mechanisms to overcome venetoclax resistance.针对表观遗传机制克服 venetoclax 耐药性。
Biochim Biophys Acta Mol Cell Res. 2021 Jul;1868(8):119047. doi: 10.1016/j.bbamcr.2021.119047. Epub 2021 May 1.
Zotero 插件